4basecare

4baseCare, an Illumina-backed Company* headquartered in Singapore, is engaged in developing cutting-edge Precision Oncology Solutions using Advanced Genomics and Next-Gen digital health technology. Taking into consideration that the clinical outcome could significantly vary across different populations, we have developed a unique set of indigenous comprehensive cancer gene panels that enables oncologists to choose the optimal precision therapies for their patients. Our coveted 🧬genomic testing portfolio assesses the tumour genomic alterations by NGS from Tissue or Liquid biopsy for Somatic Mutation Analysis and Germline Mutation Testing for Hereditary and Familial Cancer from peripheral blood to personalize patient care in Oncology. 4baseCare is backed by a highly experienced Advisory board who are leaders in genomics and technology. Among them is Lip Bu Tan, Chairman of Walden International and advisor to Yali Capital, which has invested in 4baseCare. Also on the board is Francis deSouza, a Silicon Valley tech veteran and former CEO of Illumina, who brings over 30 years of expertise in genomics, technology, and healthcare. Milestones - 4baseCare’s journey has been marked by significant milestones in both funding and growth. The company has raised $6 Million in Series A funding led by Yali Capital with participation from Mathew Cyriac. In March 2021, 4baseCare had raised $2 Million in led by Mount Judi Ventures, growX ventures, Season Two Ventures, First In Ventures, and other angel investors. 4baseCare’s test has made a significant impact in Southeast Asia, with over cancer patients taking the test. 4baseCare has collaborations with more than 300 oncologists in India. This growing network with oncologists and leading hospitals in India ensures that more patients are able to opt for personalized cancer care.